特发性矮小症 中国就医指南

Idiopathic Short Stature (ISS) is a clinical diagnosis assigned to children and adolescents who exhibit significantly reduced height—defined as a height more than 2 standard deviations (SD) below the mean for age and sex—without evidence of systemic, endocrine, nutritional, chromosomal, or skeletal disease. Crucially, ISS is a diagnosis of exclusion: growth hormone (GH) secretion is normal (confirmed by provocative testing), insulin-like growth factor 1 (IGF-1) levels are within reference ranges, bone age is appropriate for chronological age, and comprehensive evaluation—including thyroid function, cortisol, karyotype (especially in females), celiac serology, and cranial MRI when indicated—reveals no underlying pathological cause. The pathogenesis remains incompletely understood but is believed to involve complex polygenic inheritance, subtle GH–IGF-1 axis variations not detectable by standard assays, epigenetic modulation, and potentially non-pathological extremes of normal growth variation. Some studies suggest variants in genes regulating growth plate chondrogenesis (e.g., NPR2, ACAN, SHOX enhancer regions) may contribute to a subset of ISS cases, though these are not routinely screened in clinical practice. Epidemiologically, ISS accounts for approximately 60–80% of all referrals to pediatric endocrinology for short stature, with an estimated prevalence of 3–5% among school-aged children globally. It affects males and females equally and has no racial predilection, though diagnostic ascertainment may vary across healthcare systems. Risk factors are primarily constitutional and familial: parental short stature (particularly mid-parental height < 5th percentile), delayed bone age, and a strong family history of late growth spurt or uncomplicated short stature increase likelihood. Importantly, psychosocial stressors, chronic low-grade inflammation, or subclinical nutritional deficits—though insufficient to meet criteria for other diagnoses—may modulate growth velocity in genetically susceptible individuals. Quality of life impact is multifaceted: children with ISS often experience heightened vulnerability to teasing, social marginalization, and internalized stigma related to height; adolescents may report diminished self-esteem, anxiety about future occupational or romantic prospects, and avoidance of physical activities. Parents frequently report significant emotional burden, financial strain from repeated evaluations, and uncertainty regarding long-term outcomes. While adult height in untreated ISS typically falls within the low-normal range (often near the 3rd–10th percentile), early identification and multidisciplinary support—including psychological counseling and realistic expectations—are essential to mitigate adverse psychosocial sequelae and optimize functional well-being.

# 特发性矮小症（ISS）治疗方案与费用明细（内分泌科）

一、非手术/保守治疗方案

适用人群：骨龄≥5岁、GH激发试验正常（峰值≥10 μg/L）、无明确器质性病因者。

• •生长激素（rhGH）治疗（一线）：

- 进阶方案（进口水针+智能注射笔）：4–8 IU/天，年均药费 ￥48,000–￥72,000； - 含配套检查：骨龄片（X线）￥120、IGF-1检测￥180/次、肝肾功能+血糖每3月1次（￥260/次）。

二、手术/介入方案

特发性矮小症无手术指征，不推荐垂体手术、骨骺阻滞或肢体延长术；此类操作属禁忌，仅适用于垂体瘤、软骨发育不全等继发性矮小，ISS患者严禁实施。

三、复杂/耐药/并发症方案

GH治疗反应不良（年增长＜5 cm）者，需排查SHOX基因缺陷、RASopathy等：

• •全外显子组测序（WES）：￥4,800–￥6,500；
• •多学科联合管理（内分泌+遗传+康复）：门诊随访年均 ￥3,200–￥5,600（含营养评估、心理干预、运动处方）。

四、方案快速选择指南

• •预算有限（＜￥3万/年）：国产rhGH + 规范监测；
• •追求依从性与舒适度：进口水针 + 远程剂量管理；
• •疗效不佳或进展缓慢：启动遗传学评估 + WES；
• •骨龄＞13岁（女）/15岁（男）：优先评估骨骺闭合状态，慎启rhGH。